Rolland D. Carlson
Amministratore Delegato presso Immunexpress, Inc.
Profilo
Rolland D.
Carlson is the founder of Mirna Therapeutics, Inc. He is currently the Chief Executive Officer at WaferGen, Inc., the President, Chief Executive Officer & Director at Immunexpress, Inc., and the Director at Pristine, Inc. Previously, he served as the President & Chief Executive Officer at Asuragen, Inc., the President, Chief Executive Officer & Director at WaferGen Bio-systems, Inc., and as a Vice President at Abbott Laboratories.
Dr. Carlson obtained his undergraduate, graduate, and doctorate degrees from Southern Illinois University.
Posizioni attive di Rolland D. Carlson
Società | Posizione | Inizio |
---|---|---|
Pristine, Inc.
Pristine, Inc. Packaged SoftwareTechnology Services Pristine, Inc. provides enterprise software solutions for smart glasses. Its product EyeSight, offers industrial and healthcare solutions. The firm offers video communication platform primarily for health care providers, delivering information and allowing communication on the device's optics. The company was founded by Kyle Samani and Patrick Kolencherry in 2013 and is headquartered in Austin, TX. | Direttore/Membro del Consiglio | 01/04/2015 |
WaferGen, Inc.
WaferGen, Inc. BiotechnologyHealth Technology WaferGen, Inc. develops novel products for cell biology and genetic analysis. The firm focuses on the development systems for gene expression, genotyping and stem cell research for the life science and pharmaceutical industries. The company was founded by Alnoor Shivji, Victor Joseph and Amjad Huda and is headquartered in Fremont, CA. | Amministratore Delegato | - |
Immunexpress, Inc.
Immunexpress, Inc. Miscellaneous Commercial ServicesCommercial Services Immunexpress, Inc. engages in development of revolutionary molecular diagnostics. The firm's SeptiCyte technology quantifies specific and multiple molecular markers from the patient?s own immune system for earlier detection and severity assessment of sepsis, as well as the better timing of drugs and other therapies. The company was founded by Richard Bruce Brandon, Roslyn Brandon and Mervyn Rees Thomas in and is headquartered in | Amministratore Delegato | 09/04/2018 |
Precedenti posizioni note di Rolland D. Carlson
Società | Posizione | Fine |
---|---|---|
ABBOTT LABORATORIES | Corporate Officer/Principal | - |
WAFERGEN BIO-SYSTEMS, INC. | Amministratore Delegato | - |
Asuragen, Inc.
Asuragen, Inc. Medical SpecialtiesHealth Technology Asuragen, Inc. develops molecular diagnostic products. Its products include AmplideX and QuantideX. It uses genomics to drive patient management through clinical testing solutions. The company was founded in March 2006 by Matthew M. Winkler and is headquartered in Austin, TX. | Amministratore Delegato | - |
Mirna Therapeutics, Inc.
Mirna Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Mirna Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of microRNA-based oncology therapeutics. Its products includes miR-34, miR-215, miR-101, miR-16, and let-7. The company was founded Matthew M. Winkler in 2007 and is headquartered in Austin, TX. | Fondatore | - |
Formazione di Rolland D. Carlson
Southern Illinois University | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 1 |
---|---|
ABBOTT LABORATORIES | Health Technology |
Aziende private | 6 |
---|---|
Mirna Therapeutics, Inc.
Mirna Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Mirna Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of microRNA-based oncology therapeutics. Its products includes miR-34, miR-215, miR-101, miR-16, and let-7. The company was founded Matthew M. Winkler in 2007 and is headquartered in Austin, TX. | Commercial Services |
WaferGen Bio-systems, Inc.
WaferGen Bio-systems, Inc. BiotechnologyHealth Technology WaferGen Bio-systems, Inc. used to provide genomic technology solutions for single-cell analysis and clinical research. The firm offered SmartChip Real-Time polymerase chain reaction (PCR) system, which provided a suite of gene expression and genome analysis technologies enabling biomarker discovery and validation on a single platform with the sensitivity and accuracy of PCR. The company was founded by Alnoor Shivji, Victor Joseph and Amjad Huda on October 22, 2002 and was headquartered in Fremont, CA. | Health Technology |
Pristine, Inc.
Pristine, Inc. Packaged SoftwareTechnology Services Pristine, Inc. provides enterprise software solutions for smart glasses. Its product EyeSight, offers industrial and healthcare solutions. The firm offers video communication platform primarily for health care providers, delivering information and allowing communication on the device's optics. The company was founded by Kyle Samani and Patrick Kolencherry in 2013 and is headquartered in Austin, TX. | Technology Services |
Asuragen, Inc.
Asuragen, Inc. Medical SpecialtiesHealth Technology Asuragen, Inc. develops molecular diagnostic products. Its products include AmplideX and QuantideX. It uses genomics to drive patient management through clinical testing solutions. The company was founded in March 2006 by Matthew M. Winkler and is headquartered in Austin, TX. | Health Technology |
WaferGen, Inc.
WaferGen, Inc. BiotechnologyHealth Technology WaferGen, Inc. develops novel products for cell biology and genetic analysis. The firm focuses on the development systems for gene expression, genotyping and stem cell research for the life science and pharmaceutical industries. The company was founded by Alnoor Shivji, Victor Joseph and Amjad Huda and is headquartered in Fremont, CA. | Health Technology |
Immunexpress, Inc.
Immunexpress, Inc. Miscellaneous Commercial ServicesCommercial Services Immunexpress, Inc. engages in development of revolutionary molecular diagnostics. The firm's SeptiCyte technology quantifies specific and multiple molecular markers from the patient?s own immune system for earlier detection and severity assessment of sepsis, as well as the better timing of drugs and other therapies. The company was founded by Richard Bruce Brandon, Roslyn Brandon and Mervyn Rees Thomas in and is headquartered in | Commercial Services |
- Borsa valori
- Insiders
- Rolland D. Carlson